Euclid Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Euclid Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-87,000	Closed	-$8.8M	–	359
2014 Q4	$8.8M	Buy	+87,000	New	+$8.45M	0.08%	225

Other funds holding IBB

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

BFA

Beaumont Financial Advisors Needham, Massachusetts $1.46B AUM 21.07% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Euclid Advisors's IBB Position: Q1 2015 in Review

Euclid Advisors sold out of iShares Biotechnology ETF (IBB) in Q1 2015, closing a stake of 87,000 shares — an estimated $8.8M sold.

Euclid Advisors first reported a position in IBB in Q4 2014 and held it in 1 quarter. The position peaked at $8.8M in Q4 2014. 399 funds tracked by Wall St. Rank hold IBB as of Q1 2015.

Euclid Advisors reported no remaining iShares Biotechnology ETF position as of Q1 2015 after selling out during the quarter.
Euclid Advisors sold 87,000 iShares Biotechnology ETF shares in Q1 2015, an estimated $8.8M.
Euclid Advisors first reported a position in iShares Biotechnology ETF in Q4 2014 and held it in 1 quarter.
Euclid Advisors's iShares Biotechnology ETF position peaked at $8.8M in Q4 2014.
399 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2015.

Based on Euclid Advisors's 13F filing for Q1 2015, filed 15 May 2015.